Search

Your search keyword '"Sikiö, Anu"' showing total 22 results
Start Over Author "Sikiö, Anu"
22 results on '"Sikiö, Anu"'

1. Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group

Author

Partanen, Anu, primary, Waage, Anders, additional, Peceliunas, Valdas, additional, Schjesvold, Fredrik, additional, Anttila, Pekka, additional, Säily, Marjaana, additional, Uttervall, Katarina, additional, Putkonen, Mervi, additional, Carlson, Kristina, additional, Haukas, Einar, additional, Sankelo, Marja, additional, Szatkowski, Damian, additional, Hansson, Markus, additional, Marttila, Anu, additional, Svensson, Ronald, additional, Axelsson, Per, additional, Lauri, Birgitta, additional, Mikkola, Maija, additional, Karlsson, Conny, additional, Abelsson, Johanna, additional, Ahlstrand, Erik, additional, Sikiö, Anu, additional, Klimkowska, Monika, additional, Matuzeviciene, Reda, additional, Fenstad, Mona Hoysaeter, additional, Ilveskero, Sorella, additional, Pelliniemi, Tarja-Terttu, additional, Nahi, Hareth, additional, and Silvennoinen, Raija, additional

Published
2024
Full Text
View/download PDF

2. RVD induction and autologous stem cell transplantation followed by lenalidomide maintenance in newly diagnosed multiple myeloma: a phase 2 study of the Finnish Myeloma Group

Author

Luoma, Sini, Anttila, Pekka, Säily, Marjaana, Lundan, Tuija, Heiskanen, Jouni, Siitonen, Timo, Kakko, Sakari, Putkonen, Mervi, Ollikainen, Hanna, Terävä, Venla, Sankelo, Marja, Partanen, Anu, Launonen, Kirsi, Räsänen, Anu, Sikiö, Anu, Suominen, Merja, Bazia, Piotr, Kananen, Kristiina, Lievonen, Juha, Selander, Tuomas, Pelliniemi, Tarja-Terttu, Ilveskero, Sorella, Huotari, Virva, Mäntymaa, Pentti, Tienhaara, Anri, Jantunen, Esa, and Silvennoinen, Raija

Published
2019
Full Text
View/download PDF

3. P898: A PROSPECTIVE PHASE 2 STUDY TO ASSESS MINIMAL RESIDUAL DISEASE AFTER IXAZOMIB, LENALIDOMIDE, DEXAMETHASONE (IRD) TREATMENT FOR NEWLY DIAGNOSED TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS

Author

Silvennoinen, Raija, primary, Partanen, Anu, additional, Waage, Anders, additional, Pečeliūnas, Valdas, additional, Schjesvold, Fredrik, additional, Anttila, Pekka, additional, Uttervall, Katarina, additional, Säily, Marjaana, additional, Putkonen, Mervi, additional, Carlson, Kristina, additional, Haukas, Einar, additional, Sankelo, Marja, additional, Szatkowski, Damian, additional, Hansson, Markus, additional, Marttila, Anu, additional, Axelsson, Per, additional, Svensson, Ronald, additional, Lauri, Birgitta, additional, Mikkola, Maija, additional, Karlsson, Conny, additional, Abelsson, Johanna, additional, Ahlstrand, Erik, additional, Sikiö, Anu, additional, Klimkowska, Monika, additional, Matuzeviciene, Reda, additional, Hoyseter Fenstad, Mona, additional, Ilveskero, Sorella, additional, and Nahi, Hareth, additional

Published
2023
Full Text
View/download PDF

4. Comparison of <scp>CD34</scp> + cell mobilization, blood graft cellular composition, and post‐transplant outcome in myeloma patients mobilized with filgrastim or pegfilgrastim added to low‐dose cyclophosphamide: A prospective multicenter study

Author

Kuittinen Taru, Mäntymaa Pentti, Siitonen Timo, Penttilä Karri, Pelkonen Jukka, Putkonen Mervi, Valtola Jaakko, Varmavuo Ville, Turunen Antti, Silvennoinen Raija, Sankelo Marja, Pyörälä Marja, Partanen Anu, Jantunen Esa, and Sikiö Anu

Subjects
medicine.medical_specialty, Cyclophosphamide, biology, Bortezomib, business.industry, Immunology, Urology, Hematology, Filgrastim, medicine.disease, CD19, 03 medical and health sciences, 0302 clinical medicine, Apheresis, 030220 oncology & carcinogenesis, PEG ratio, medicine, biology.protein, Immunology and Allergy, business, Pegfilgrastim, Multiple myeloma, 030215 immunology, medicine.drug
Abstract

Background Scarce data exist on the impact of granulocyte-colony stimulating factor (G-CSF) type on the mobilizing capacity of CD34+ cells, graft cellular composition, and outcome in myeloma (MM) patients. Patients and methods In this prospective multicenter study, 70 patients with MM received filgrastim (FIL) and 20 patients received pegfilgrastim (PEG) as a G-CSF after low-dose cyclophosphamide. Flow cytometry was used to analyze the mobilization of CD34+ cells and cellular composition of blood grafts, hematologic recovery, and survival after auto-SCT according to the G-CSF choice. Results The CD34+ cell yield of the first apheresis was higher in the FIL group (5.3 vs. 4.2 × 106 /kg, p = .025). The better mobilizing capacity was observed in the FIL group especially after bortezomib-based induction based on the higher first apheresis yield of CD34+ cells (7.5 vs. 4.4 × 106 /kg, p = .001). The median CD19+ cell count (1.0 vs. 0.4 × 106 /kg, p = .010) and the number of CD3+ T lymphocytes (43.1 vs. 31.8 × 106 /kg, p = .122) in the infused graft were higher in the patients mobilized with FIL. Both early (day +15) (56 vs. 108 × 109 /L, p = .002) and later platelet recovery at 6 months (191 vs. 226 × 109 /L, p = .026) were faster in the PEG group. Conclusion G-CSF type seems to impact on the mobilization capacity and cellular composition of infused graft and also platelet recovery post-transplant. A randomized study might be warranted to verify the effects of G-CSF choice in the mobilization field.

Published
2021
Full Text
View/download PDF

5. Impact of the number of cryopreserved CD34+ cells in the infused blood grafts on hematologic recovery and survival in myeloma patients after autologous stem cell transplantation: Experience from the GOA study

Author

Partanen, Anu, primary, Turunen, Antti, additional, Silvennoinen, Raija, additional, Valtola, Jaakko, additional, Pyörälä, Marja, additional, Siitonen, Timo, additional, Sikiö, Anu, additional, Putkonen, Mervi, additional, Sankelo, Marja, additional, Penttilä, Karri, additional, Kuittinen, Taru, additional, Mäntymaa, Pentti, additional, Pelkonen, Jukka, additional, Jantunen, Esa, additional, and Varmavuo, Ville, additional

Published
2022
Full Text
View/download PDF

6. P-222: A prospective phase 2 study to assess minimal residual disease after ixazomib plus lenalidomide plus dexamethasone (IRd) treatment for newly diagnosed transplant eligible multiple myeloma patients

Author

Silvennoinen, Raija, primary, Waage, Anders, additional, Peceliunas, Valdas, additional, Schjesvold, Fredrik, additional, Anttila, Pekka, additional, Uttervall, Katarina, additional, Säily, Marjaana, additional, Putkonen, Mervi, additional, Carlson, Kristina, additional, Haukas, Einar, additional, Sankelo, Marja, additional, Partanen, Anu, additional, Szatkowski, Damian, additional, Hansson, Markus, additional, Marttila, Anu, additional, Svensson, Ronald, additional, Axelsson, Per, additional, Lauri, Birgitta, additional, Mikkola, Maija, additional, Karlsson, Conny, additional, Abelsson, Johanna, additional, Ahlstrand, Erik, additional, Sikiö, Anu, additional, and Nahi, Hareth, additional

Published
2022
Full Text
View/download PDF

7. Impact of the number of cryopreserved CD34+ cells in the infused blood grafts on hematologic recovery and survival in myeloma patients after autologous stem cell transplantation: Experience from the GOA study.

Author

Partanen, Anu, Turunen, Antti, Silvennoinen, Raija, Valtola, Jaakko, Pyörälä, Marja, Siitonen, Timo, Sikiö, Anu, Putkonen, Mervi, Sankelo, Marja, Penttilä, Karri, Kuittinen, Taru, Mäntymaa, Pentti, Pelkonen, Jukka, Jantunen, Esa, and Varmavuo, Ville

Subjects
STEM cell transplantation, OVERALL survival, CRYOPRESERVATION of cells, PROGRESSION-free survival, BLOOD cells
Abstract

Background: Prospective data on the impact of CD34+ cell loss during cryopreservation and the amount of cryopreserved CD34+ cells infused after high‐dose therapy on hematologic recovery and post‐transplant outcome in multiple myeloma (MM) are scarce. Patients and methods: This post‐hoc study aimed to investigate factors associating with CD34+ cell loss during cryopreservation and the effects of the infusion of a very low number (<1.0 × 106/kg, group A), low number (1–1.9 × 106/kg, group B), and optimal number (≥2 × 106/kg, group C) of thawed viable CD34+ cells on hematologic recovery, progression free survival, and overall survival after autologous stem cell transplantation among 127 patients with MM. Results: In group C, pegfilgrastim use (P = 0.001), plerixafor use (P = 0.039), and older age ≥ 60 years (P = 0.026) were associated with less loss of CD34+ cells during cryopreservation. Better mobilization efficacy correlated with greater CD34+ cell loss in group B (P = 0.013 and P = 0.001) and in group C (P < 0.001 and P < 0.001). Early platelet engraftment was slowest in group A (20 d vs 12 d in group B vs 11 d in group C, P = 0.003). The infused viable CD34+ cell count <1.0 × 106/kg seemed not to have influence on PFS (P = 0.322) or OS (P = 0.378) in MM patients. Conclusions: Cryopreservation impacts significantly on the CD34+ cell loss. A very low number of graft viable CD34+ cells did not affect PFS or OS. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

8. Carfilzomib, Elotuzumab and Dexamethasone for Relapsed or Refractory Myeloma Patients

Author

Silvennoinen, Raija Helena, Nahi, Hareth, Anttila , Pekka, Koskenvesa, Perttu, Lievonen, Juha, Marttila, Anu, Varmavuo, Ville, Sikiö, Anu, Nurmi, Marita, Säily, Marjaana, Partanen, Anu, Sankelo, Marja, Luoma, Sini, Mäntymaa, Pentti, Ilveskero, Sorella, Eshoj, Henrik, Kongsgaard Nielsen, Lene, Jantunen, Esa, and Heckman, Caroline

Subjects
medicine.medical_specialty, Immunology, Neutropenia, Biochemistry, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Refractory, Internal medicine, medicine, Clinical endpoint, Elotuzumab, Multiple myeloma, 030304 developmental biology, Lenalidomide, 0303 health sciences, business.industry, Cell Biology, Hematology, Pomalidomide, medicine.disease, Carfilzomib, 3. Good health, chemistry, 030220 oncology & carcinogenesis, business, medicine.drug
Abstract

Introduction: Due to its heterogenous nature including evolving mutations, multiple myeloma (MM) is still an incurable disease. Several novel agents have been introduced during the last decade resulting in prolonged median overall survival (OS) up to 7-8 years. Nevertheless, disease relapse is expected and eventually all patients will end up with relapsed and refractory multiple myeloma (RRMM). To benefit from all available drugs, novel combinations should be evaluated for feasibility and efficacy. Bortezomib (B), elotuzumab and dexamethasone (d) showed superiority to Bd with progression-free survival (PFS) of 9.7 vs. 6.9 months, respectively, without excessive toxicity. In this study we investigated the safety and efficacy of carfilzomib (K), elotuzumab (E) and dexamethasone (D) combination (KED) in RRMM patients. Patients and methods: Altogether 15 RRMM patients after 1-3 prior lines including B or/and lenalidomide (Len) were included. Refractoriness for B or/and Len was allowed. The main exclusion criteria were age > 74 years, absolute neutrophil count < 1.0 x 109/L and platelet count < 75 x 109/L, hemoglobin < 80 g/L, active heart disease or left ventricular ejection fraction < 40%. Carfilzomib was given once weekly 20 mg/m2 on C1D1 and thereafter 70 mg/m2 in 28-day cycles on day 1, 8, 15 in cycles 1-8, thereafter on day 1, 15 combined with weekly elotuzumab 10 mg/kg on day 1, 8, 15 in cycles 1-2, thereafter on day 1, 15; dexamethasone 40 mg on day 1, 8, 15, 22 in cycles 1-8, thereafter on day 1, 15. Treatment continued until progression (PD) or toxicity. The primary endpoint was overall response rate (ORR). If patients achieved at least very good partial remission (VGPR) the quality of response was assessed with high-sensitivity multicolour flow cytometry according to the 8-color EuroFlow protocol. Patients also completed health-related quality of life (QoL) questionnaires at day 1 and 15 through cycle 1-8. Results: The median age of patients was 69 (62-73) years, 80% (12/15) had received upfront autologous stem cell transplantation. The median number of prior lines was 2 (1-3). Proportion of Len or B refractory was 47% and 20% were double refractory. FISH, beside at diagnosis, was repeated and 73% (11/15) had at least one of following aberrations: del17p, t(4;14), t(14;16), t(14;20) or +1q. Del17 was found in 27% (4/15) of patients and +1q was frequent (67%). After the median follow-up of 18 months the ORR (at least partial response, PR) was 87% (13/15). Seven patients (47%) achieved VGPR, of these 6 patients continue in study, one was withdrawn due to thrombotic microangiopathy (TMA). The median measurable MRD level of VGPR patients was 0.005% (range 0.002-0.15%, one undetectable), and 0.003% (range 0.0007-0.26%) after one year, respectively. Regarding the rest of the patients 6 achieved PR, one minimal response and one was refractory. The median time to response was 7 (3-16) weeks. The estimated median PFS is 22 months (CI 95% 17.4-27.1). The OS has not been reached. Two (13%) grade 2 infusion reactions during first infusion were noticed. One patient developed autoimmune hemolytic anemia (AIHA), but recovered and continued KD without reappearance of AIHA. Grade 1-2 respiratory infections appeared in 66% of patients. Altogether 22 severe adverse events (SAE) grade 3-4 were reported in 60% (9/15) patients, one third were infections. Grade 3-4 neutropenia was found in 40% which is slightly more compared to reports when elotuzumab is combined with Len or pomalidomide. The overall QoL trajectory was kept steady throughout the 8 cycles. Diarrhea and dyspnoe were reported during treatment, but with full recovery before starting the next cycle which had no consequence for further treatment. Conclusion: The primary endpoint, at least PR, was reached in 87% of study patients. After a median follow-up of 18 months KED resulted in durable responses in 7 of these 15 patients (47%), despite the high frequency of adverse cytogenetics by FISH, 67% with +1q and 27% with del17p. The number of non-hematological SAEs was 60%. We noticed 2 serious unexpected adverse reactions, AIHA and TMA with convulsions, and an additional case of pulmonary embolism, in responding patients. We recommend careful monitoring for the signs of microangiopathy and hemolysis. In summary, KED resulted in a high ORR, which was durable in approximately 50% of the patients. Side effects were manageable and randomized trials with KED are warranted. Disclosures Silvennoinen: Cancer patients Finland: Honoraria; Takeda: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria; Celgene: Consultancy, Honoraria, Research Funding; BMS: Consultancy, Honoraria, Research Funding; Amgen: Consultancy, Honoraria, Research Funding. Anttila:Janssen: Honoraria, Other: Advisory Board; BMS: Research Funding; Takeda: Honoraria, Research Funding; Sanofi: Research Funding; Celgene: Honoraria, Research Funding; Amgen: Honoraria, Research Funding. Lievonen:Amgen, Celgene, BMS, Sanofi, Takeda: Consultancy; Celgene, Janssen, Novartis, Amgen: Honoraria; Cancer Association Finland: Honoraria. Varmavuo:Abbvie, Roche, Celgene, Amgen, Sanofi: Consultancy. Säily:Boehringer Ingelheim: Honoraria; Janssen Cilag: Honoraria; Takeda: Honoraria; Pfizer: Honoraria; Sanofi: Honoraria; Roche: Honoraria; Celgene: Honoraria; Abbvie: Honoraria; Amgen: Honoraria. Partanen:Takeda: Other: Scientific Advisory Board Meeting; Behring: Honoraria; Abbvie: Honoraria, Other: Scientific Advisory Board Meeting. Sankelo:Celgene, Amgen, Sanofi: Other: Congress travel support. Luoma:Amgen, Janssen. Incyte: Other: Advisory Boards. Jantunen:Celgene: Honoraria; Amgen: Honoraria, Other: Advisory Board; Sanofi: Honoraria; TEVA: Other: Advisory Board; Takeda: Other: Advisory Board. Heckman:Celgene: Research Funding; Novartis: Research Funding; Oncopeptides: Research Funding; Orion Pharma: Research Funding; Innovative Mediicines Initiative project Harmony: Research Funding.

Published
2020
Full Text
View/download PDF

9. Autograft cellular composition and outcome in myeloma patients: Results of the prospective multicenter GOA study

Author

Turunen, Antti, primary, Silvennoinen, Raija, additional, Partanen, Anu, additional, Valtola, Jaakko, additional, Siitonen, Timo, additional, Putkonen, Mervi, additional, Sankelo, Marja, additional, Pyörälä, Marja, additional, Kuittinen, Taru, additional, Penttilä, Karri, additional, Sikiö, Anu, additional, Savolainen, Eeva‐Riitta, additional, Mäntymaa, Pentti, additional, Pelkonen, Jukka, additional, Varmavuo, Ville, additional, and Jantunen, Esa, additional

Published
2021
Full Text
View/download PDF

11. A Prospective Phase 2 Study to Assess Minimal Residual Disease after Ixazomib, Lenalidomide and Dexamethasone Treatment for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients

Author

Silvennoinen, Raija Helena, primary, Waage, Anders, additional, Peceliunas, Valdas, additional, Schjesvold, Fredrik, additional, Anttila, Pekka, additional, Säily, Marjaana, additional, Putkonen, Mervi, additional, Carlson, Kristina, additional, Haukaas, Einar, additional, Sankelo, Marja, additional, Partanen, Anu, additional, Szatkowski, Damian L., additional, Hansson, Markus, additional, Marttila, Anu, additional, Ahlberg, Lucia, additional, Axelsson, Per, additional, Lauri, Birgitta, additional, Mikkola, Maija Helena, additional, Karlsson, Conny, additional, Abelsson, Johanna, additional, Ahlstrand, Erik, additional, Sikiö, Anu, additional, Klimkowska, Monika, additional, Matuzeviciene, Reda, additional, Hoysaeter Fenstad, Mona, additional, Ilveskero, Sorella, additional, and Nahi, Hareth, additional

Published
2020
Full Text
View/download PDF

12. CD34+ cell mobilization, blood graft composition, and posttransplant recovery in myeloma patients compared to non‐Hodgkinʼs lymphoma patients: results of the prospective multicenter GOA study

Author

Turunen, Antti, primary, Partanen, Anu, additional, Valtola, Jaakko, additional, Ropponen, Antti, additional, Siitonen, Timo, additional, Kuittinen, Outi, additional, Kuitunen, Hanne, additional, Putkonen, Mervi, additional, Sankelo, Marja, additional, Keskinen, Leena, additional, Savolainen, Eeva‐Riitta, additional, Pyörälä, Marja, additional, Kuittinen, Taru, additional, Silvennoinen, Raija, additional, Penttilä, Karri, additional, Sikiö, Anu, additional, Vasala, Kaija, additional, Mäntymaa, Pentti, additional, Pelkonen, Jukka, additional, Varmavuo, Ville, additional, and Jantunen, Esa, additional

Published
2020
Full Text
View/download PDF

14. A phase 2 study of carfilzomib plus elotuzumab plus dexamethasone for myeloma patients relapsed after 1-3 prior treatment lines

Author

Silvennoinen, Raija, primary, Majumder, Muntasir Mamun, additional, Tsallos, Dimitrios, additional, Nahi, Hareth, additional, Anttila, Pekka, additional, Partanen, Anu, additional, Luoma, Sini, additional, Sikiö, Anu, additional, Nurmi, Marita, additional, Varmavuo, Ville, additional, Säily, Marjaana, additional, Sankelo, Marja, additional, Jantunen, Esa, additional, Pelliniemi, Tarja-Terttu, additional, Ilveskero, Sorella, additional, Eshoj, Henrik Rode, additional, Nielsen, Lene Kongsgaard, additional, Eldfors, Samuli, additional, Leppä, Aino-Maija, additional, and Heckman, Caroline, additional

Published
2019
Full Text
View/download PDF

15. A Phase 2 Study of Carfilzomib Plus Elotuzumab Plus Dexamethasone for Myeloma Patients Relapsed after 1-3 Prior Treatment Lines

Author

Silvennoinen, Raija Helena, primary, Tsallos, Dimitrios, additional, Nahi, Hareth, additional, Anttila, Pekka, additional, Koskenvesa, Perttu, additional, Lievonen, Juha, additional, Räsänen, Anu, additional, Varmavuo, Ville, additional, Sikiö, Anu, additional, Nurmi, Marita, additional, Säily, Marjaana, additional, Partanen, Anu, additional, Sankelo, Marja, additional, Luoma, Sini, additional, Ilveskero, Sorella, additional, Pelliniemi, Tarja-Terttu, additional, Jantunen, Esa, additional, Majumder, Muntasir M, additional, Eldfors, Samuli, additional, Leppä, Maija, additional, and Heckman, Caroline A, additional

Published
2018
Full Text
View/download PDF

16. RVD + ASCT + Lenalidomide Maintenance Benefits Patients without High-Risk Cytogenetics and Results in Recovery of the Normal Plasma Cell Composition in Bone Marrow

Author

Silvennoinen, Raija, primary, Anttila, Pekka, additional, Säily, Marjaana, additional, Lundan, Tuija, additional, Heiskanen, Jouni, additional, Siitonen, Timo, additional, Kakko, Sakari, additional, Putkonen, Mervi, additional, Ollikainen, Hanna, additional, Terävä, Venla, additional, Partanen, Anu, additional, Launonen, Kirsi, additional, Räsänen, Anu, additional, Sikiö, Anu, additional, Suominen, Merja, additional, Bazia, Piotr, additional, Kananen, Kristiina, additional, Lievonen, Juha, additional, Selander, Tuomas, additional, Västrik, Imre, additional, Pelliniemi, Tarja-Terttu, additional, Porkka, Kimmo, additional, Remes, Kari, additional, and Jantunen, Esa, additional

Published
2016
Full Text
View/download PDF

17. A Prospective Phase 2 Study to Assess Immunophenotypic Remission after Lenalidomide-Based Induction Followed By ASCT and Lenalidomide Maintenance in Patients with Newly Diagnosed Multiple Myeloma

Author

Silvennoinen, Raija, primary, Anttila, Pekka, additional, Säily, Marjaana, additional, Lundan, Tuija, additional, Heiskanen, Jouni, additional, Siitonen, Timo, additional, Kakko, Sakari, additional, Putkonen, Mervi, additional, Ollikainen, Hanna, additional, Terävä, Venla, additional, Partanen, Anu, additional, Launonen, Kirsi, additional, Räsänen, Anu, additional, Sikiö, Anu, additional, Suominen, Merja, additional, Bazia, Piotr, additional, Kananen, Kristiina, additional, Selander, Tuomas, additional, Kuittinen, Taru, additional, Porkka, Kimmo, additional, Remes, Kari, additional, and Jantunen, Esa, additional

Published
2015
Full Text
View/download PDF

18. A Randomized Comparison of Low-Dose Cyclophosphamide + G-CSF Versus G-CSF Alone Mobilization after Lenalidomide-Bortezomib-Dexamethasone (RVD) Induction in Multiple Myeloma

Author

Silvennoinen, Raija, primary, Lundan, Tuija, additional, Anttila, Pekka, additional, Heiskanen, Jouni, additional, Säily, Marjaana, additional, Siitonen, Timo, additional, Kakko, Sakari, additional, Ollikainen, Hanna, additional, Vanhatalo, Seppo, additional, Putkonen, Mervi, additional, Terävä, Venla, additional, Kutila, Anu, additional, Partio, Mari, additional, Launonen, Kirsi, additional, Räsänen, Anu, additional, Sikiö, Anu, additional, Suominen, Merja, additional, Bazia, Piotr, additional, Kananen, Kristiina, additional, Kuittinen, Taru, additional, Porkka, Kimmo, additional, Remes, Kari, additional, and Jantunen, Esa, additional

Published
2014
Full Text
View/download PDF

19. Assessment of molecular remission rate after bortezomib plus dexamethasone induction treatment and autologous stem cell transplantation in newly diagnosed multiple myeloma patients

Author

Silvennoinen, Raija, primary, Kairisto, Veli, additional, Pelliniemi, Tarja‐Terttu, additional, Putkonen, Mervi, additional, Anttila, Pekka, additional, Säily, Marjaana, additional, Sikiö, Anu, additional, Opas, Jorma, additional, Penttilä, Karri, additional, Kuittinen, Taru, additional, Honkanen, Tuomo, additional, Lundán, Tuija, additional, Juvonen, Vesa, additional, Luukkaala, Tiina, additional, and Remes, Kari, additional

Published
2012
Full Text
View/download PDF

21. Teriparatide treatment complicated by malignant myeloma.

Author

Koski, Anna-Mari, Sikiö, Anu, and Forslund, Terje

Abstract

Recombinant human parathyroid hormone (1-34) (rhPTH 1-34), teriparatide (Forsteo in Europe), is a new compound that has been introduced and shown to be successful in the treatment of osteoporosis. The mechanisms of action include a pulsative influence on the RANKL/OPG system resulting in osteoblast activation and increased bone formation by teriparatide. In malignant myeloma there is an imbalance between osteoclast and osteoblast activity with involvement of the RANKL/OPG system among others. We report a case with monoclonal gammopathy of uncertain significance (MGUS) who developed malignant myeloma after teriparatide treatment and we suggest that in addition to malignant myeloma and smouldering myeloma, MGUS should also be considered contraindicated for teriparatide treatment. [ABSTRACT FROM AUTHOR]

Published
2010

22. Impact of the number of cryopreserved CD34 + cells in the infused blood grafts on hematologic recovery and survival in myeloma patients after autologous stem cell transplantation: Experience from the GOA study.

Author

Partanen A, Turunen A, Silvennoinen R, Valtola J, Pyörälä M, Siitonen T, Sikiö A, Putkonen M, Sankelo M, Penttilä K, Kuittinen T, Mäntymaa P, Pelkonen J, Jantunen E, and Varmavuo V

Subjects
Humans, Hematopoietic Stem Cell Mobilization, Transplantation, Autologous, Prospective Studies, Antigens, CD34 metabolism, Cryopreservation, Graft Survival, Hematopoietic Stem Cell Transplantation, Multiple Myeloma therapy, Heterocyclic Compounds pharmacology
Abstract

Background: Prospective data on the impact of CD34 + cell loss during cryopreservation and the amount of cryopreserved CD34 + cells infused after high-dose therapy on hematologic recovery and post-transplant outcome in multiple myeloma (MM) are scarce., Patients and Methods: This post-hoc study aimed to investigate factors associating with CD34 + cell loss during cryopreservation and the effects of the infusion of a very low number (<1.0 × 10 6 /kg, group A), low number (1-1.9 × 10 6 /kg, group B), and optimal number (≥2 × 10 6 /kg, group C) of thawed viable CD34 + cells on hematologic recovery, progression free survival, and overall survival after autologous stem cell transplantation among 127 patients with MM., Results: In group C, pegfilgrastim use (P = 0.001), plerixafor use (P = 0.039), and older age ≥ 60 years (P = 0.026) were associated with less loss of CD34 + cells during cryopreservation. Better mobilization efficacy correlated with greater CD34 + cell loss in group B (P = 0.013 and P = 0.001) and in group C (P < 0.001 and P < 0.001). Early platelet engraftment was slowest in group A (20 d vs 12 d in group B vs 11 d in group C, P = 0.003). The infused viable CD34 + cell count <1.0 × 10 6 /kg seemed not to have influence on PFS (P = 0.322) or OS (P = 0.378) in MM patients., Conclusions: Cryopreservation impacts significantly on the CD34 + cell loss. A very low number of graft viable CD34 + cells did not affect PFS or OS., (© 2022 Wiley Periodicals LLC.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results